biodesix inc - BDSX

BDSX

Close Chg Chg %
13.31 -0.17 -1.28%

Closed Market

13.14

-0.17 (1.28%)

Volume: 30.50K

Last Updated:

Apr 17, 2026, 4:00 PM EDT

Company Overview: biodesix inc - BDSX

BDSX Key Data

Open

$13.02

Day Range

13.00 - 13.80

52 Week Range

3.44 - 20.21

Market Cap

$131.21M

Shares Outstanding

9.86M

Public Float

3.96M

Beta

0.57

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$4.73

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

62.22K

 

BDSX Performance

1 Week
 
0.08%
 
1 Month
 
-11.66%
 
3 Months
 
66.75%
 
1 Year
 
19.67%
 
5 Years
 
-96.61%
 

BDSX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About biodesix inc - BDSX

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

BDSX At a Glance

Biodesix, Inc.
919 West Dillon Road
Louisville, Colorado 80027
Phone 1-303-417-0500 Revenue 88.50M
Industry Medical/Nursing Services Net Income -35,265,000.00
Sector Health Services 2025 Sales Growth 24.082%
Fiscal Year-end 12 / 2026 Employees 334
View SEC Filings

BDSX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.58
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.742
Enterprise Value to Sales 1.188
Total Debt to Enterprise Value 0.693

BDSX Efficiency

Revenue/Employee 264,967.066
Income Per Employee -105,583.832
Receivables Turnover 9.794
Total Asset Turnover 0.937

BDSX Liquidity

Current Ratio 1.865
Quick Ratio 1.79
Cash Ratio 1.095

BDSX Profitability

Gross Margin 75.248
Operating Margin -31.374
Pretax Margin -39.848
Net Margin -39.848
Return on Assets -37.347
Return on Equity -383.086
Return on Total Capital -50.10
Return on Invested Capital -46.668

BDSX Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 103.502
Total Debt to Total Assets 81.242
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 101.556
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biodesix Inc - BDSX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
38.21M 49.09M 71.32M 88.50M
Sales Growth
-29.89% +28.46% +45.30% +24.08%
Cost of Goods Sold (COGS) incl D&A
17.16M 15.88M 20.93M 21.91M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.60M 5.51M 5.46M 5.60M
Depreciation
1.62M 3.52M 3.45M 3.57M
Amortization of Intangibles
1.98M 1.98M 2.01M 2.03M
COGS Growth
-48.13% -7.47% +31.84% +4.65%
Gross Income
21.05M 33.21M 50.39M 66.59M
Gross Income Growth
-1.75% +57.74% +51.73% +32.15%
Gross Profit Margin
+55.10% +67.66% +70.65% +75.25%
2022 2023 2024 2025 5-year trend
SG&A Expense
71.56M 74.51M 84.65M 94.36M
Research & Development
13.10M 9.99M 9.56M 12.00M
Other SG&A
58.46M 64.52M 75.09M 82.36M
SGA Growth
+17.80% +4.12% +13.61% +11.47%
Other Operating Expense
- - - -
-
Unusual Expense
6.98M 1.32M 1.62M 387.00K
EBIT after Unusual Expense
(57.48M) (42.62M) (35.88M) (28.15M)
Non Operating Income/Expense
109.00K 6.00K 73.00K 604.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
8.07M 9.54M 7.12M 7.72M
Interest Expense Growth
+79.06% +18.14% -25.33% +8.36%
Gross Interest Expense
8.07M 9.54M 7.12M 7.72M
Interest Capitalized
- - - -
-
Pretax Income
(65.45M) (52.15M) (42.93M) (35.27M)
Pretax Income Growth
-51.64% +20.32% +17.67% +17.86%
Pretax Margin
-171.27% -106.23% -60.19% -39.85%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(65.45M) (52.15M) (42.93M) (35.27M)
Minority Interest Expense
- - - -
-
Net Income
(65.45M) (52.15M) (42.93M) (35.27M)
Net Income Growth
-51.64% +20.32% +17.67% +17.86%
Net Margin Growth
-171.27% -106.23% -60.19% -39.85%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(65.45M) (52.15M) (42.93M) (35.27M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(65.45M) (52.15M) (42.93M) (35.27M)
EPS (Basic)
-31.089 -12.701 -6.6216 -4.6702
EPS (Basic) Growth
+1.44% +59.15% +47.87% +29.47%
Basic Shares Outstanding
2.11M 4.11M 6.48M 7.55M
EPS (Diluted)
-31.089 -12.701 -6.6216 -4.6702
EPS (Diluted) Growth
+1.44% +59.15% +47.87% +29.47%
Diluted Shares Outstanding
2.11M 4.11M 6.48M 7.55M
EBITDA
(46.91M) (35.79M) (28.80M) (22.16M)
EBITDA Growth
-29.80% +23.70% +19.52% +23.05%
EBITDA Margin
-122.76% -72.91% -40.39% -25.05%

Snapshot

Average Recommendation BUY Average Target Price 32.50
Number of Ratings 5 Current Quarters Estimate -0.847
FY Report Date 06 / 2026 Current Year's Estimate -3.08
Last Quarter’s Earnings -1.06 Median PE on CY Estimate N/A
Year Ago Earnings -4.67 Next Fiscal Year Estimate -1.934
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate -0.85 -0.74 -3.08 -1.93
High Estimates -0.67 -0.64 -2.51 -1.39
Low Estimate -0.99 -0.82 -3.62 -2.53
Coefficient of Variance -16.02 -10.82 -14.76 -22.58

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 4
OVERWEIGHT 0 0 0
HOLD 0 0 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Biodesix Inc - BDSX

Date Name Shares Transaction Value
May 21, 2025 Jack W. Schuler Director 20,194,935 Open market or private purchase of non-derivative security Non-derivative transaction at $0.27 per share 5,452,632.45
May 21, 2025 Jack W. Schuler Director 20,918,174 Open market or private purchase of non-derivative security Non-derivative transaction at $0.34 per share 7,112,179.16

Biodesix Inc in the News